Screening of Compounds for Activity against HIV: A Collaborative Study-Reference-Cited by-同舟云学术

Screening of Compounds for Activity against HIV: A Collaborative Study

Published:1991-10 Issue:5 Volume:2 Page:287-293
ISSN:2040-2066
Container-title:Antiviral Chemistry and Chemotherapy
language:en
Short-container-title:Antivir Chem Chemother

Author:

Holmes H. C.¹,Mahmood N.²,Karpas A.³,Petrik J.³,Kinchington D.⁴,O'Connor T.⁴,Jeffries D. J.⁴,Desmyter J.⁵,De Clercq E.⁵,Pauwels R.⁵,Hay A.⁶

Affiliation:

1. WHO Collaborating Centre for AIDS, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK

2. MRC Collaborative Centre, Burtonhole Lane, Mill Hill, London NW7 1AD, UK

3. Department of Haematology, Clinical School, University of Cambridge, Hills Road, Cambridge CB2 2QL, UK

4. Department of Virology, Medical College of St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK

5. Rega Institute for Medical Research, Katholieke Universität Leuven, Minderbroederstraat 10, B-3000 Leuven, Belgium

6. National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK

Abstract

The collaborative study was undertaken to examine the sensitivity of a range of tests used in assessing the antiviral activities of compounds against human immunodeficiency virus (HIV). A panel of 20 compounds with diverse antiviral activities against HIV were tested under code at three antiviral testing centres supported by the Medical Research Council's AIDS Directed Programme and at the European Community Centralised Facility (ECCF) for New Antiviral Compounds against AIDS in Belgium. Compounds known to have major anti-HIV activity ranked high in all assays, with the exception of the glucosidase inhibitors and certain nucleoside analogues. Results of two assays based on MT4 cells (centre IV) showed a high degree of similarity, despite the use of distinct HIV-1 (HTLV-IIIB) and HIV-2 (ROD) viruses. Considerable similarity was also observed between the assays based on HTLV-IIIRF in C8166 cells (centres I and II). Other assays performed at centre II and at centre III had enhanced sensitivity for glycosidase inhibitors. The differences in anti-HIV activity that were observed may be attributable to specific properties of the cell lines used and particular testing methodologies. The use of more than one type of assay is advisable in order not to miss compounds with low to moderate activity against HIV.

Publisher

SAGE Publications

Link

http://journals.sagepub.com/doi/pdf/10.1177/095632029100200503

Reference27 articles.

1. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro

2. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro

3. Differential Patterns of Intracellular Metabolism of 2′,3′-Didehydro-2′,3′-dideoxythymidine and 3′-Azido-2′,3′-dideoxythymidine, Two Potent Anti-human Immunodeficiency Virus Compounds

4. The Enzymatic Synthesis and Anti-HIV-1 Activity of 9-β-D-2′,3′-Dideoxynucleosides of N(6)-Substituted Purines

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Road to Fortovase. A History of Saquinavir, the First Human Immunodeficiency Virus Protease Inhibitor;Handbook of Experimental Pharmacology;2000

2. Xylans of Industrial and Biomedical Importance;Biotechnology and Genetic Engineering Reviews;1999-04

3. Antiviral Activity of 2-Hydroxy Fatty Acids;Antiviral Chemistry and Chemotherapy;1996-06

4. Drug Evaluation: Anti-infectives: Saquinavir: A review of its development, pharmacological properties and clinical use;Expert Opinion on Investigational Drugs;1996-02

5. Initial in vitro screening of drug candidates for their potential antiviral activities;Virology Methods Manual;1996